Andere Sprachen Curasight A/S

Aktien

CURAS

DK0061295797

CURAS

Schlusskurs NORDIC GROWTH MARKET Andere Börsenplätze 00:00:00 25.04.2024			% 5 Tage	% 1. Jan.
9.98 ^DKK	+0.20%		-0.70%	-43.77%

16.04.	Curasight A/S gibt die Genehmigung des Antrags auf klinische Prüfung (CTA) für eine Phase-2-Studie mit uTRACE bei Prostatakrebspatienten bekannt	CI
12.04.	Curasight A/S kündigt Änderungen im Verwaltungsrat an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	22.04.
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	16.04.
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	16.04.
Curasight announces change in the Board of Directors	12.04.
Curasight A/S Announces Board Changes	12.04.
BioStock: Curasight cancels rights issue and evaluates alternative financing	13.03.
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	11.03.
Notice of Annual General Meeting 2024	06.03.
The subscription period in Curasight's rights issue begins today	23.02.
Curasight publishes information memorandum in connection with forthcoming rights issue	22.02.
Annual Report for the fiscal year 2023	22.02.
Year-end report October - December 2023	22.02.
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	19.02.
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13.02.
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	13.02.
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	13.02.
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	13.02.
BioStock: Curasight gets first milestone payment from Curium	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Curasight A/S

Aktien

CURAS

DK0061295797

CURAS

Andere Sprachen

Filter